Our pipeline

We have an exciting and balanced pipeline underpinned by great science.

Latest quarterly updates

Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.


167

projects in our pipeline

7

new molecular entities in our late-stage pipeline

1

new molecular entity approval in the last quarter



Phase III/LCM Projects: refers to assets that are pivotal in Phase II/III, or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets (removed when launched in all applicable major markets).

Filter By:

Oncology (as at 29 April 2020)

Phase I

Phase I

  • AZD0466haematological and solid tumours
  • AZD1390glioblastoma
  • AZD4573haematalogical malignancies
  • AZD5153solid tumours, haematological malignancies
  • AZD5991haematalogical malignancies
  • AZD7648haematological and solid tumours
  • AZD9496oestrogen receptor +ve breast cancer
  • Calquence + ceralasertib (AZD6738)haematological malignancies
  • Calquence + danvatirsenhaematological malignancies
  • Imfinzi + adavosertibsolid tumours
  • Imfinzi + Koselugo (selumetinib)solid tumours
  • Imfinzi + RT (platform)CLOVERlocally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + tremelimumabsolid tumours
  • Imfinzi + tremelimumab + CTx1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • IPH5201solid tumours
  • MEDI1191solid tumours
  • MEDI2228multiple myeloma
  • MEDI5083solid tumours
  • MEDI5395solid tumours
  • oleclumab + TagrissoEGFRm NSCLC

Phase II

Phase II

  • (oleclumab+CTx) or (Imfinzi+oleclumab+CTx)metastatic pancreatic cancer
  • adavosertibovarian cancer, solid tumours
  • AZD2811solid tumours, haematological malignancies
  • AZD4635prostate cancer
  • AZD9833oestrogen receptor +ve breast cancer
  • capivasertibbreast cancer
  • capivasertibprostate cancer
  • Imfinzi (platform)COASTnon small cell lung cancer
  • Imfinzi (platform)NeoCOASTnon small cell lung cancer
  • Imfinzi + AZD4635prostate cancer
  • Imfinzi + AZD5069 orImfinzi + danvatirsenhead and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + FOLFOX + bevacizumabCOLUMBIA 11st-line metastatic microsatellite-stable colorectal cancer
  • Imfinzi + LynparzaBAYOU1st-line unresectable stage IV bladder cancer
  • Imfinzi + LynparzaORION1st-line metastatic non-small cell lung cancer
  • Imfinzi + MEDI0457head and neck squamous cell carcinoma
  • Imfinzi + monalizumabsolid tumours
  • Imfinzi + oleclumabsolid tumours
  • Imfinzi + tremelimumabbiliary tract, oesophageal
  • Imfinzi + tremelimumabgastric cancer
  • Lynparza + adavosertibsolid tumours
  • Lynparza + ceralasertib (AZD6738)VIOLETTEbreast cancer
  • Lynparza + ImfinziMEDIOLAovarian cancer, breast cancer, gastic cancer and small-cell lung cancer
  • MEDI5752solid tumours
  • oleclumab + AZD4635prostate cancer
  • Tagrisso + or selumetinib or savolitinib)TATTONadvanced EGFRm non-small cell lung cancer
  • Tagrisso + savolitinibSAVANNAHadvanced EGFRm non-small cell lung cancer

Phase III

Phase III

  • capivasertib + CTxCAPItello-2901st-line metastatic triple negative breast cancer
  • EnhertuDESTINY-Breast01HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1
  • Imfinzi + tremelimumabHIMALAYA1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumabKESTREL1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab + SoCNILE1st-line urothelial cancer
  • Imfinzi +/- tremelimumab + CRTADRIATIC1st-line limited-stage small-cell lung cancer
  • Imfinzi +/- tremelimumab + CTxPOSEIDON1st-line non-small cell lung cancer
  • Koselugo (selumetinib)SPRINTpaediatric neurofibromatosis type-1
  • Lumoxiti3rd-line hairy cell leukaemia
  • Lynparza + Imfinzi + bevacizumabDUO-O1st-line ovarian cancer

2020欧洲杯体育在线平台LCM Projects

LCM Projects

  • CalquenceECHO1st-line mantle cell lymphoma
  • CalquenceASCENDrelapsed/refractory chronic lymphocytic leukaemia
  • CalquenceELEVATE-RRrelapsed/refractory chronic lymphocytic leukaemia, high risk
  • CalquenceELEVATE-TN1st-line chronic lymphocytic leukaemia
  • Calquence + venetoclax + obinutuzumab1st-line chronic lymphocytic leukaemia
  • EnhertuHER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer
  • EnhertuDESTINY-Breast03HER2-positive, unresectable and/or metastatic breast cancer subjects previously treated with trastuzumab and taxane
  • EnhertuDESTINY-CRC01HER2-expressing advanced colorectal cancer
  • EnhertuDESTINY-Gastric01HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens
  • EnhertuDESTINY-Gastric02HER2-positive gastric cancer that cannot be surgically removed or has spread
  • EnhertuDESTINY-Breast02HER2-positive, Unresectable and/or Metastatic Breast Cancer Pretreated With Prior Standard of Care HER2 Therapies, Including T-DM1
  • EnhertuDESTINY-Breast04HER2-low, unresectable and/or metastatic breast cancer subjects
  • ImfinziCALLAlocally-advanced cervical cancer
  • ImfinziPOTOMACnon muscle invasive bladder cancer
  • ImfinziPACIFIClocally advanced (stage III) NSCLC
  • Imfinzisolid tumours
  • ImfinziPEARL1st-line metastatic non-small cell lung cancer
  • Imfinzi (platform)BEGONIA1st-line metastatic triple negative breast cancer
  • Imfinzi (platform)MAGELLAN1st-line metastatic non-small cell lung cancer
  • Imfinzi + azacitidinemyelodysplastic syndrome
  • Imfinzi + CRTPACIFIC-2locally-advanced (stage III) NSCLC
  • Imfinzi + CRTPACIFIC-5 (China)locally-advanced (stage III) NSCLC
  • Imfinzi + CTxNIAGARAmuscle invasive bladder cancer
  • Imfinzi + CTxTOPAZ-11st-line biliary tract cancer
  • Imfinzi + CTx neoadjuvantAEGEANlocally-advanced (stage I-III) NSCLC
  • Imfinzi + SoCCASPIAN1st-line extensive-stage small-cell lung cancer
  • Imfinzi + VEGFEMERALD-2adjuvant hepatocellular carcinoma
  • Imfinzi + VEGF + TACEEMERALD-1locoregional hepatocellular carcinoma
  • Imfinzi post-SBRTPACIFIC-4stage I/II non-small cell lung cancer
  • LynparzaPROfoundprostate cancer
  • LynparzaSOLO-11st-line BRCAm ovarian cancer
  • LynparzaSOLO-22nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • LynparzaOlympiAgBRCA adjuvant breast cancer
  • LynparzaOlympiADgBRCA metastatic breast cancer
  • LynparzaPOLOpancreatic cancer
  • LynparzaSOLO-3gBRCA PSR ovarian cancer
  • Lynparza (basket)MK-7339-002 / LYNK002HRRm cancer
  • Lynparza + abirateronePROpelprostate cancer
  • Lynparza + cediranibCONCERTOrecurrent platinum-resistant ovarian cancer
  • TagrissoADAURAadjuvant EGFRm non-small cell lung cancer
  • TagrissoLAURAstage 3 EGFRm non-small cell lung cancer
  • Tagrisso + CTxFLAURA21st-line advanced EGFRm non-small cell lung cancer

Cardiovascular, Renal and Metabolism (as at 29 April 2020)

Phase I

Phase I

  • AZD2373nephropathy
  • AZD2693NASH
  • AZD6615CV disease
  • AZD8233CV disease
  • AZD9977CV disease
  • MEDI6570cardiovascular disease
  • MEDI7219type-2 diabetes

Phase II

Phase II

  • AZD4831heart failure with a preserved ejection fraction
  • AZD5718coronary artery disease
  • AZD8601cardiovascular disease
  • cotadutidetype-2 diabetes, obesity and NASH
  • MEDI3506diabetic kidney disease
  • MEDI5884cardiovascular disease
  • MEDI6012cardiovascular disease
  • verinuradchronic kidney disease

Phase III

Phase III

  • Epanovasevere hypertriglyceridaemia
  • Lokelmahyperkalaemia
  • roxadustatOLYMPUSROCKIESanaemia in chronic kidney disease/end-stage renal disease

LCM Projects

LCM Projects

  • Brilinta/BriliqueTHALESacute ischaemic stroke or transient ischaemic attack
  • Brilinta/BriliqueHESTIAprevention of vaso-occlusive crises in paediatric patients with sickle cell disease
  • Brilinta/BriliqueTHEMIScardiovascular outcomes trial in patients with coronary artery disease and type-2 diabetes without a previous history of myocardial infarction or stroke
  • Bydureon BCise (autoinjector)type-2 diabetes
  • Farxiga/ForxigaDapa-CKDrenal outcomes and cardiovascular mortality in patients with chronic kidney disease
  • Farxiga/ForxigaDapa-HFworsening heart failure or cardiovascular death in patients with chronic heart failure (HFrEF)
  • Farxiga/ForxigaDECLARE-TIMI 58cardiovascular outcomes trial in patients with type-2 diabetes
  • Farxiga/ForxigaDELIVERworsening HF or CV death in patients with chronic heart failure (HFpEF)
  • Farxiga/ForxigaDEPICTtype-1 diabetes
  • Farxiga/ForxigaDETERMINE-Preservedheart failure with preserved ejection fraction (HFpEF)
  • Farxiga/ForxigaDETERMINE-Reducedheart failure with reduced ejection fraction (HFrEF)
  • Qternmet XR/Qtrilmet (saxagliptin/dapagliflozin metformin)type-2 diabetes
  • roxadustatanaemia in myelodysplastic syndrome
  • roxadustatchemotherapy induced anaemia
  • Xigduo XR/Xigduotype-2 diabetes

Respiratory & Immunology (as at 29 April 2020)

Phase I

Phase I

  • AZD0284psoriasis/respiratory
  • AZD0449asthma
  • AZD1402asthma
  • AZD5634cystic fibrosis
  • AZD8154asthma
  • MEDI5117 Chinarheumatoid arthritis

Phase II

Phase II

  • abediterolasthma/chronic obstructive pulmonary disease
  • anifrolumablupus nephritis
  • anifrolumabsystemic lupus erythematosus (subcutaneous)
  • AZD7986chronic obstructive pulmonary disease
  • AZD9567rheumatoid arthritis/respiratory
  • MEDI3506chronic obstructive pulmonary disease and atopic dermatitis
  • navafenterol (AZD8871)chronic obstructive pulmonary disease
  • tezepelumabatopic dermatitis
  • tezepelumabchronic obstructive pulmonary disease
  • velsecorat (AZD7594)asthma/chronic obstructive pulmonary disease

Phase III

Phase III

  • anifrolumabTULIPsystemic lupus erythematosus
  • Bevespi Aerosphere (PT003)chronic obstructive pulmonary disease
  • Breztri Aerosphere (PT010)chronic obstructive pulmonary disease
  • FasenraCALIMA SIROCCO ZONDA BISE BORAGREGALE MIRACLEsevere uncontrolled asthma
  • nirsevimabpassive RSV immunisation
  • PT027asthma
  • tezepelumabNAVIGATOR SOURCEsevere uncontrolled asthma

LCM Projects

LCM Projects

  • Breztri (PT010)asthma
  • Duaklir Genuairchronic obstructive pulmonary disease
  • FasenraMANDARAeosinophilic granulomatosis with polyangiitis
  • FasenraOSTROORCHID (Japan/China)nasal polyposis
  • FasenraRESOLUTEchronic obstructive pulmonary disease
  • SymbicortSYGMAas-needed use in mild asthma

Other (as at 29 April 2020)

Phase I

Phase I

  • AZD4041opioid use disorder
  • MEDI0618osteoarthritis pain
  • MEDI1341parkinson's disease
  • MEDI1814alzheimer’s disease

Phase II

Phase II

  • MEDI7352osteoarthritis pain and painful diabetic neuropathy
  • suvratoxumabprevention of nosocomial Staphylococcus aureus pneumonia

Phase III

Phase III

    2020欧洲杯体育在线平台LCM Projects

    LCM Projects

    • Nexiumstress ulcer prophylaxis

    Removed since last quarter

    Veeva ID: Z4-12937     
    Date of next review: September 2020